Phase 2a Study Shows BTX 1801 Eradicates Staphylococcus Aureus
•Top-line data showed that two different BTX 1801 formulations (ointment and gel) were safe, well tolerated and successful at eradicating Staphylococcus aureus.
•Eradication rates as high as 76.2% were obtained at Day 7 for BTX 1801 ointment, with eradication effects extending through to Day 28 of the study to 23.8%, despite no treatment after Day 5
•Botanix continues to assess the clinical utility of synthetic CBD for the treatment of a variety of infections and also develop its proprietary CBD analog assets
Ann: Phase 2a Study Shows BTX 1801 Eradicates S. Aureus, page-7
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $651.6M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 37.3¢ | 35.3¢ | $1.417M | 3.891M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 110000 | 35.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.0¢ | 457035 | 7 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |